The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hemoglobinopathy-Global Market Insights and Sales Trends 2024
Synopsis
Hemoglobinopathies are a diverse set of congenital blood ailments that are a consequence of disparities in the structure and/or synthesis of hemoglobin. Hemoglobinopathies are genetic single-gene disorders that lead to an abnormal structure of one of the globin chains of the hemoglobin molecule, rendering it unable to carry oxygen through the body, which leads to anemia or other medical abnormalities. The most common hemoglobinopathies are sickle cell disease, alpha thalassemia, and beta thalassemia.
The global Hemoglobinopathy market size is expected to reach US$ 368.1 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Hemoglobinopathy in various end use industries. The expanding demands from the Hospitals, Diagnostic Laboratories and Clinics,, are propelling Hemoglobinopathy market. Sickle Cell Disease, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Alpha Thalassemia segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hemoglobinopathy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hemoglobinopathy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hemoglobinopathy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hemoglobinopathy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hemoglobinopathy covered in this report include Abbott Diagnostics, Bio-Rad Laboratories, Danaher Corporation, Mindray Medical International, Nexcelom Bioscience, Nihon Kohden, PerkinElmer, Siemens Healthineers and Sysmex Corporation, etc.
The global Hemoglobinopathy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Diagnostics
Bio-Rad Laboratories
Danaher Corporation
Mindray Medical International
Nexcelom Bioscience
Nihon Kohden
PerkinElmer
Siemens Healthineers
Sysmex Corporation
Global Hemoglobinopathy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hemoglobinopathy market, Segment by Type:
Sickle Cell Disease
Alpha Thalassemia
Beta Thalassemia
Global Hemoglobinopathy market, by Application
Hospitals
Diagnostic Laboratories
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hemoglobinopathy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hemoglobinopathies are a diverse set of congenital blood ailments that are a consequence of disparities in the structure and/or synthesis of hemoglobin. Hemoglobinopathies are genetic single-gene disorders that lead to an abnormal structure of one of the globin chains of the hemoglobin molecule, rendering it unable to carry oxygen through the body, which leads to anemia or other medical abnormalities. The most common hemoglobinopathies are sickle cell disease, alpha thalassemia, and beta thalassemia.
The global Hemoglobinopathy market size is expected to reach US$ 368.1 million by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The market is mainly driven by the significant applications of Hemoglobinopathy in various end use industries. The expanding demands from the Hospitals, Diagnostic Laboratories and Clinics,, are propelling Hemoglobinopathy market. Sickle Cell Disease, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Alpha Thalassemia segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hemoglobinopathy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hemoglobinopathy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hemoglobinopathy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hemoglobinopathy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hemoglobinopathy covered in this report include Abbott Diagnostics, Bio-Rad Laboratories, Danaher Corporation, Mindray Medical International, Nexcelom Bioscience, Nihon Kohden, PerkinElmer, Siemens Healthineers and Sysmex Corporation, etc.
The global Hemoglobinopathy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Diagnostics
Bio-Rad Laboratories
Danaher Corporation
Mindray Medical International
Nexcelom Bioscience
Nihon Kohden
PerkinElmer
Siemens Healthineers
Sysmex Corporation
Global Hemoglobinopathy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hemoglobinopathy market, Segment by Type:
Sickle Cell Disease
Alpha Thalassemia
Beta Thalassemia
Global Hemoglobinopathy market, by Application
Hospitals
Diagnostic Laboratories
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hemoglobinopathy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hemoglobinopathy
1.1 Hemoglobinopathy Market Overview
1.1.1 Hemoglobinopathy Product Scope
1.1.2 Hemoglobinopathy Market Status and Outlook
1.2 Global Hemoglobinopathy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hemoglobinopathy Market Size by Region (2018-2029)
1.4 Global Hemoglobinopathy Historic Market Size by Region (2018-2023)
1.5 Global Hemoglobinopathy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hemoglobinopathy Market Size (2018-2029)
1.6.1 North America Hemoglobinopathy Market Size (2018-2029)
1.6.2 Europe Hemoglobinopathy Market Size (2018-2029)
1.6.3 Asia-Pacific Hemoglobinopathy Market Size (2018-2029)
1.6.4 Latin America Hemoglobinopathy Market Size (2018-2029)
1.6.5 Middle East & Africa Hemoglobinopathy Market Size (2018-2029)
2 Hemoglobinopathy Market by Type
2.1 Introduction
2.1.1 Sickle Cell Disease
2.1.2 Alpha Thalassemia
2.1.3 Beta Thalassemia
2.2 Global Hemoglobinopathy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hemoglobinopathy Historic Market Size by Type (2018-2023)
2.2.2 Global Hemoglobinopathy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hemoglobinopathy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hemoglobinopathy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hemoglobinopathy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hemoglobinopathy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hemoglobinopathy Revenue Breakdown by Type (2018-2029)
3 Hemoglobinopathy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Diagnostic Laboratories
3.1.3 Clinics
3.2 Global Hemoglobinopathy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hemoglobinopathy Historic Market Size by Application (2018-2023)
3.2.2 Global Hemoglobinopathy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hemoglobinopathy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hemoglobinopathy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hemoglobinopathy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hemoglobinopathy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hemoglobinopathy Revenue Breakdown by Application (2018-2029)
4 Hemoglobinopathy Competition Analysis by Players
4.1 Global Hemoglobinopathy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hemoglobinopathy as of 2022)
4.3 Date of Key Players Enter into Hemoglobinopathy Market
4.4 Global Top Players Hemoglobinopathy Headquarters and Area Served
4.5 Key Players Hemoglobinopathy Product Solution and Service
4.6 Competitive Status
4.6.1 Hemoglobinopathy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Diagnostics
5.1.1 Abbott Diagnostics Profile
5.1.2 Abbott Diagnostics Main Business
5.1.3 Abbott Diagnostics Hemoglobinopathy Products, Services and Solutions
5.1.4 Abbott Diagnostics Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Diagnostics Recent Developments
5.2 Bio-Rad Laboratories
5.2.1 Bio-Rad Laboratories Profile
5.2.2 Bio-Rad Laboratories Main Business
5.2.3 Bio-Rad Laboratories Hemoglobinopathy Products, Services and Solutions
5.2.4 Bio-Rad Laboratories Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.2.5 Bio-Rad Laboratories Recent Developments
5.3 Danaher Corporation
5.3.1 Danaher Corporation Profile
5.3.2 Danaher Corporation Main Business
5.3.3 Danaher Corporation Hemoglobinopathy Products, Services and Solutions
5.3.4 Danaher Corporation Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.3.5 Mindray Medical International Recent Developments
5.4 Mindray Medical International
5.4.1 Mindray Medical International Profile
5.4.2 Mindray Medical International Main Business
5.4.3 Mindray Medical International Hemoglobinopathy Products, Services and Solutions
5.4.4 Mindray Medical International Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.4.5 Mindray Medical International Recent Developments
5.5 Nexcelom Bioscience
5.5.1 Nexcelom Bioscience Profile
5.5.2 Nexcelom Bioscience Main Business
5.5.3 Nexcelom Bioscience Hemoglobinopathy Products, Services and Solutions
5.5.4 Nexcelom Bioscience Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.5.5 Nexcelom Bioscience Recent Developments
5.6 Nihon Kohden
5.6.1 Nihon Kohden Profile
5.6.2 Nihon Kohden Main Business
5.6.3 Nihon Kohden Hemoglobinopathy Products, Services and Solutions
5.6.4 Nihon Kohden Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.6.5 Nihon Kohden Recent Developments
5.7 PerkinElmer
5.7.1 PerkinElmer Profile
5.7.2 PerkinElmer Main Business
5.7.3 PerkinElmer Hemoglobinopathy Products, Services and Solutions
5.7.4 PerkinElmer Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.7.5 PerkinElmer Recent Developments
5.8 Siemens Healthineers
5.8.1 Siemens Healthineers Profile
5.8.2 Siemens Healthineers Main Business
5.8.3 Siemens Healthineers Hemoglobinopathy Products, Services and Solutions
5.8.4 Siemens Healthineers Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.8.5 Siemens Healthineers Recent Developments
5.9 Sysmex Corporation
5.9.1 Sysmex Corporation Profile
5.9.2 Sysmex Corporation Main Business
5.9.3 Sysmex Corporation Hemoglobinopathy Products, Services and Solutions
5.9.4 Sysmex Corporation Hemoglobinopathy Revenue (US$ Million) & (2018-2023)
5.9.5 Sysmex Corporation Recent Developments
6 North America
6.1 North America Hemoglobinopathy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hemoglobinopathy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hemoglobinopathy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hemoglobinopathy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hemoglobinopathy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hemoglobinopathy Market Dynamics
11.1 Hemoglobinopathy Industry Trends
11.2 Hemoglobinopathy Market Drivers
11.3 Hemoglobinopathy Market Challenges
11.4 Hemoglobinopathy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
